Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:14:37 EDT Sat 18 Jul 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:CADL - CANDEL THERAPEUTICS INC - https://ir.candeltx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CADL - Q1.19.50·12.004.510.18+0.707.42,380.123,46614,8329.355  10.50  9.2611.35  4.3519:35:40Jul 0815 min RT 2¢

Recent Trades - Last 10 of 14832
Time ETExPriceChangeVolume
19:35:40Q10.200.722
18:33:48Q10.19020.710225
18:04:29Q10.250.774,250
17:23:39Q10.24950.7695200
16:36:41Q10.210.7325
16:35:17Q10.210.7350
16:34:37Q10.210.735
16:17:22Q10.190.7120
16:10:05Q10.180.701
16:10:05Q10.180.701

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-07-08 16:05U:CADLNews ReleaseCandel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01 16:05U:CADLNews ReleaseCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-30 08:05U:CADLNews ReleaseCandel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
2026-06-25 08:05U:CADLNews ReleaseCandel Therapeutics Appoints Mark Sims as Chief Commercial Officer
2026-06-02 08:05U:CADLNews ReleaseCandel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
2026-06-01 16:05U:CADLNews ReleaseCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-15 16:05U:CADLNews ReleaseCandel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
2026-05-14 08:05U:CADLNews ReleaseCandel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-13 08:05U:CADLNews ReleaseCandel Therapeutics to Present at Upcoming Investor Conferences
2026-05-04 08:05U:CADLNews ReleaseCandel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
2026-05-01 16:05U:CADLNews ReleaseCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-29 08:05U:CADLNews ReleaseCandel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
2026-04-02 16:05U:CADLNews ReleaseCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-17 08:05U:CADLNews ReleaseCandel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
2026-03-12 08:05U:CADLNews ReleaseCandel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
2026-03-09 08:05U:CADLNews ReleaseCandel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
2026-03-02 16:05U:CADLNews ReleaseCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-24 08:05U:CADLNews ReleaseCandel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston
2026-02-19 21:40U:CADLNews ReleaseCandel Therapeutics Announces Pricing of Public Offering
2026-02-19 16:05U:CADLNews ReleaseCandel Therapeutics Announces Proposed $100 Million Public Offering